Kurt Reyes
Obesity Medicine · McKinney, TXNPI 1275684094
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 30.7% of the total. Reporting peaked in 2020 at $1,427 and has fallen 78.4% since, to $308 in 2025.
Across 192 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$542
- AstraZeneca$524
- Kvk-tech, Inc.$429
- Pfizer$228
- AbbVie$222
- plus $1K from 16 others
What the payments were for
- Consulting fees$251%
- Food & beverage$4,44799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $1,371 |
| Lilly USA, LLC | 38 | $542 |
| AstraZeneca | 15 | $524 |
| Kvk-tech, Inc. | 14 | $429 |
| Pfizer | 8 | $228 |
| AbbVie(2 entities) | 13 | $222 |
| Genentech USA, Inc. | 3 | $168 |
| Amarin Pharma, Inc. | 10 | $160 |
| Boehringer Ingelheim | 10 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $123 |
| Almatica Pharma LLC | 6 | $105 |
| Idorsia Pharmaceuticals US Inc | 6 | $101 |
| Vivus LLC | 5 | $59 |
| Corcept Therapeutics | 3 | $56 |
| Abbott | 3 | $55 |
| Amgen | 3 | $45 |
| Johnson & Johnson | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Bayer | 1 | $16 |
| Stryker | 1 | $15 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 19 | $26,580 |
| OzempicSemaglutide | 19 | $20,202 |
| Zolpidem Tartrate | 12 | $908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $542 | $26,58019 claims |
| Novo NordiskOzempic | $1,371 | $20,20219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Texason file to place this against a meaningful peer group, so we don't.
Other obesity medicine in McKinney
- Sully DrotarDallas$194K
- Sameer MuraliHouston$93K
- Alan GlombickiHouston$93K
- Suzanne CudaSan Antonio$40K
- Michael SegerSan Antonio$16K
- Richa MittalFrisco$8K
- Laura MontesMcAllen$1K
- Christina UlbrichDallas$793
- Michele CaveneePlano$363
- Ryan RatliffTyler$332
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.